You are here: Home » PTI Stories » National » News
Business Standard

Piramal Ent Q3 net profit up 21%, to raise Rs 2,000 crore

Topics
Business Finance

Press Trust of India  |  Mumbai 

Ajay Piramal-controlled Piramal Enterprises today said that the company has seen a robust performance in financial services and pharmaceutical verticals in the quarter ended December 31 and plans to raise Rs 2,000 crore in the near future.

Piramal Enterprises reported a 21.37 per cent rise in consolidated net profit to Rs 490.47 crore for the December quarter. Consolidated revenue from operations also rose to Rs 2,858.36 crore for the quarter under review, against Rs 2,341.74 crore in the same period a year ago.

"We have continued to deliver a strong performance since past many quarters. Out of our Rs 7,000 crore capital raising plans, we have successfully raised Rs 5,000 crore through QIP in the last quarter and are raising another Rs 2,000 crore shortly. We will deploy Rs 5,000 crore in financial services, Rs 1,000 crore in the pharma sector and remaining Rs 1,000 crore will used for general purposes," Piramal Enterprises chairman Ajay Piramal told PTI here.

The consistency in our performance is an outcome of the robustness of our business model and sharp focus on quality, compliance, legal and risk mitigation across our businesses, Piramal added.

The company's income from financial services jumped 46 per cent at Rs 1,316 crore for the quarter under review. The growth in income was primarily driven by increase in size of loan book, which grew by 68 per cent over last year to Rs 38,036 crore.

Construction finance now accounts for 58 per cent of its real estate loan book. Its corporate finance group (CFG) loan book grew by 134 per cent to Rs 6,392 crore and emerging corporate lending loan book nearly doubled to Rs 619 crore as on December 31.

The company received housing finance licence in August and disbursed Rs 491 crore in Q3 FY18. Housing loans approved but not disbursed stands at Rs 680 crore as on December 2017.

During Q3 FY18, the company's pharma segment revenues grew by 7 per cent to Rs 1,022 crore, as compared with Rs 954 crore in same period last year. Revenue from India consumer products for the quarter grew by 17 per cent to Rs 100 crore.

"The domestic pharma sector only grew by over 5 per cent last year due to a slowdown and GST impact, but it will grow faster this year as the industry has started picking up", Piramal said.

The company has also forayed into hospitality sector and committed Rs 1,200 crore of loans across marquee Hotel Assets in Gurugram, Bangalore and Pune.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, January 30 2018. 18:35 IST
RECOMMENDED FOR YOU